Milbemax vet. (1 - 5 kg)

1 x 4 pc

Tablet

Active substance

Praziquantel : 25 mg

Milbemycinoxim : 2,5 mg

ATC code

QP54AB51 Milbemycin oxime, comb.

QP54AB Milbemycins

QP54A Macrocyclic lactones

QP54 Endectocides

QP Antiparasitic products, insecticides and repellents

Species

Dogs (≥ 0.5 kg).

Indications

For dogs with, or at risk from mixed infections of cestodes, gastrointestinal nematodes, eyeworm, lungworms and/or heartworm. This veterinary medicinal product is only indicated when use against cestodes and nematodes or prevention of heartworm disease/angiostrongylosis is indicated at the same time.

Cestodes

Treatment of tapeworms: Dipylidium caninum, Taenia spp., Echinococcus spp., Mesocestoides spp.

Gastrointestinal nematodes Treatment of:

Hookworm: Ancylostoma caninum

Roundworms: Toxocara canis, Toxascaris leonina

Whipworm: Trichuris vulpis

Eyeworm

Treatment of Thelazia callipaeda (see specific treatment schedule under section 4.9 “Amount(s) to be administered and administration route”).

Lungworms

Treatment of:

Angiostrongylus vasorum (Reduction of the level of infection by immature adult (L5) and adult parasite stages; see specific treatment and prevention disease schedules under section 4.9 “Amount(s) to be administered and administration route”),

Crenosoma vulpis (Reduction of the level of infection).

Heartworm

Prevention of heartworm disease (Dirofilaria immitis) if concomitant treatment against cestodes is indicated.

Dose to be administered and administration route

Oral use.

Underdosing could result in ineffective use and may favour resistance development.

To ensure a correct dosage, body weight should be determined as accurately as possible.

Minimum recommended dose rate: 0.5 mg of milbemycin oxime and 5 mg of praziquantel per kg are given once. The veterinary medicinal product should be administered with or after some food.

Depending on the bodyweight of the dog, the practical dosing is as follows:

Weight	Tablets
0.5 – 1 kg	½ tablet
> 1 - 5 kg	1 tablet
> 5-10 kg	2 tablets

In cases when heartworm disease prevention is used and at the same time treatment against tapeworm is required, the veterinary medicinal product can replace the monovalent veterinary medicinal product for the prevention of heartworm disease.

For treatment of Angiostrongylus vasorum infections, milbemycin oxime should be given four times at weekly intervals. It is recommended, where concomitant treatment against cestodes is indicated, to treat once with the veterinary medicinal product and continue with the monovalent veterinary medicinal product containing milbemycin oxime alone, for the remaining three weekly treatments.

In endemic areas administration of the veterinary medicinal product every four weeks will prevent angiostrongylosis by reducing immature adult (L5) and adult parasite burden, where concomitant treatment against cestodes is indicated.

For the treatment of Thelazia callipaeda, milbemycin oxime should be given in 2 treatments, seven days apart. Where concomitant treatment against cestodes is indicated, the veterinary medicinal product can replace the monovalent veterinary medicinal product containing milbemycin oxime alone.

Adverse reactions

Dogs:

Very rare (<1 animal / 10 000 animals	Digestive tract disorders (such as Diarrhoea,
	Drooling, Emesis) Hypersensitivity reaction
treated, including isolated
reports):	Neurological disorders (such as Ataxia and
	Muscle tremor) Systemic disorders (such as Anorexia and

	Lethargy)

Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or its local representative or the national competent authority via the national reporting system. See the package leaflet for respective contact details.